Abbvie Deutschland Gmbh and Co Kg

Anna Linsenmeier

Andreas Haupt

Wilfried Martin Braje

Karla Drescher

Helmut Mack

Margaretha Henrica Maria Bakker

Gisela Backfisch

Ana Lucia Relo

Viktor Lakics

Günter Blaich

Thomas Erhard

Raimund Peter

Hannes Koolman

Xiaona Zhao

Jincheng Wang

Lynette Smyth

The present invention relates to compound of formula (I) as tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, useful for modulating the 5-HTreceptor and preventing and/or treating conditions and disorders that respond to the modulation of the 5-HTreceptor. The present invention also relates to methods for producing compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for preventing or treating conditions and disorders that respond to the modulation of the 5-HTreceptor by administering compounds of formula (1) or pharmaceutical compositions thereof.

Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators

The present invention relates to tricyclic hexahydrodiazepinoquinolines, such as compounds of formula (I), carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HTreceptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HTreceptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HTreceptor, and processes for preparing such compounds and compositions. 

Hexahydrodiazepinoquinolines carrying a substituted alkyl radical

Growing community of inventors

Ludwigshafen, Germany

Anna Linsenmeier